Key Points
- CEO Christopher Peetz sold 7,098 shares on Jan. 22 at an average price of $93.33, generating ~$662,456 and reducing his stake by 4.15% to 163,733 shares (valued ~ $15.28M).
- Multiple senior executives also sold shares the same day (including the COO and CFO), a block of insider selling that is likely weighing on sentiment around the stock.
- Mirum posted a quarter with an EPS beat and revenue up 47.1%, but remains loss-making on GAAP metrics; analysts are broadly positive (consensus "Moderate Buy" with a ~ $102.58 price target).
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $86,423.58. Following the completion of the sale, the senior vice president directly owned 3,042 shares of the company's stock, valued at approximately $283,909.86. This trade represents a 23.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Mirum Pharmaceuticals Price Performance
Shares of MIRM opened at $94.29 on Friday. The firm has a market cap of $4.85 billion, a PE ratio of -109.64 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 1-year low of $36.88 and a 1-year high of $96.84. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The firm has a fifty day simple moving average of $77.33 and a two-hundred day simple moving average of $70.64.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals's revenue was up 47.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.30) earnings per share. On average, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Evercore ISI reiterated an "outperform" rating and issued a $101.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday. Raymond James Financial reiterated a "strong-buy" rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Morgan Stanley upped their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 9th. Finally, Robert W. Baird raised their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an "outperform" rating in a report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $102.58.
Check Out Our Latest Stock Analysis on MIRM
Trending Headlines about Mirum Pharmaceuticals
Here are the key news stories impacting Mirum Pharmaceuticals this week:
- Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
- Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
- Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
- Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
- Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert
Institutional Trading of Mirum Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of MIRM. Wellington Management Group LLP raised its position in shares of Mirum Pharmaceuticals by 566.8% during the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company's stock valued at $57,965,000 after purchasing an additional 672,118 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Mirum Pharmaceuticals by 709.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company's stock worth $44,889,000 after buying an additional 536,674 shares in the last quarter. Voloridge Investment Management LLC increased its stake in Mirum Pharmaceuticals by 2,116.6% in the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company's stock worth $28,560,000 after buying an additional 371,999 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in Mirum Pharmaceuticals during the third quarter valued at about $23,250,000. Finally, William Blair Investment Management LLC purchased a new position in shares of Mirum Pharmaceuticals in the third quarter valued at about $22,965,000.
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
